These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10877833)

  • 21. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin.
    Mishima K; Mazar AP; Gown A; Skelly M; Ji XD; Wang XD; Jones TR; Cavenee WK; Huang HJ
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8484-9. PubMed ID: 10890917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo.
    Kargiotis O; Chetty C; Gogineni V; Gondi CS; Pulukuri SM; Kyritsis AP; Gujrati M; Klopfenstein JD; Dinh DH; Rao JS
    Int J Oncol; 2008 Nov; 33(5):937-47. PubMed ID: 18949356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer.
    Hildenbrand R; Dilger I; Hörlin A; Stutte HJ
    Pathol Res Pract; 1995 Jun; 191(5):403-9. PubMed ID: 7479358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells.
    Subramanian R; Gondi CS; Lakka SS; Jutla A; Rao JS
    Int J Oncol; 2006 Apr; 28(4):831-9. PubMed ID: 16525631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer.
    Zhang L; Zhao ZS; Ru GQ; Ma J
    World J Gastroenterol; 2006 Jul; 12(25):3970-6. PubMed ID: 16810742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model.
    Das A; Boyd N; Jones TR; Talarico N; McGuire PG
    Arch Ophthalmol; 2004 Dec; 122(12):1844-9. PubMed ID: 15596589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined chemo/anti-angiogenic cancer therapy against Lewis lung carcinoma (3LL) pulmonary metastases.
    Datta A; Kitson RP; Xue Y; al-Atrash G; Mazar AP; Jones TR; Goldfarb RH
    In Vivo; 2002; 16(6):451-7. PubMed ID: 12494889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.
    Kobayashi H; Ohi H; Shinohara H; Sugimura M; Fujii T; Terao T; Schmitt M; Goretzki L; Chucholowski N; Jänicke F
    Br J Cancer; 1993 Mar; 67(3):537-44. PubMed ID: 8382511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urokinase plasminogen activator induces smooth muscle cell migration: key role of growth factor-like domain.
    Stepanova V; Bobik A; Bibilashvily R; Belogurov A; Rybalkin I; Domogatsky S; Little PJ; Goncharova E; Tkachuk V
    FEBS Lett; 1997 Sep; 414(2):471-4. PubMed ID: 9315743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies.
    Rabbani SA; Xing RH
    Int J Oncol; 1998 Apr; 12(4):911-20. PubMed ID: 9499455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis.
    Kobayashi H; Sugino D; She MY; Ohi H; Hirashima Y; Shinohara H; Fujie M; Shibata K; Terao T
    Eur J Biochem; 1998 May; 253(3):817-26. PubMed ID: 9654084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.
    Stahl A; Mueller BM
    Cancer Res; 1994 Jun; 54(11):3066-71. PubMed ID: 8187097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Green tea polyphenols modulate secretion of urokinase plasminogen activator (uPA) and inhibit invasive behavior of breast cancer cells.
    Slivova V; Zaloga G; DeMichele SJ; Mukerji P; Huang YS; Siddiqui R; Harvey K; Valachovicova T; Sliva D
    Nutr Cancer; 2005; 52(1):66-73. PubMed ID: 16091006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes.
    Navaratna D; Menicucci G; Maestas J; Srinivasan R; McGuire P; Das A
    FASEB J; 2008 Sep; 22(9):3310-7. PubMed ID: 18559877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
    Frandsen TL; Holst-Hansen C; Nielsen BS; Christensen IJ; Nyengaard JR; Carmeliet P; Brünner N
    Cancer Res; 2001 Jan; 61(2):532-7. PubMed ID: 11212246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
    Albo D; Berger DH; Rothman VL; Tuszynski GP
    J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
    Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR).
    Liu D; Overbey D; Watkinson L; Giblin MF
    Bioconjug Chem; 2009 May; 20(5):888-94. PubMed ID: 19354275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.